SECUKINUMAB (Cosentyx) prior authorization at Florida Blue
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Florida Blue requires Interleukin-17A Antagonist prior-authorization documentation for SECUKINUMAB (Cosentyx): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Florida Blue reviews SECUKINUMAB (Cosentyx) prior authorizations against its medical policy for Interleukin-17A Antagonist. Florida Blue-specific context: BCBS licensee for Florida (~5M members). Owned by GuideWell. Prime Therapeutics is the PBM (BCBS-aggregated PBM serving 19 BCBS plans). Florida OIR oversight. Largest ACA Marketplace participant in FL.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-17A Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Florida Blue's medical policy URL referenced in the cover letter
Florida Blue's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Marketplace narrow-network denials (BlueCare, myBlue)
- Step therapy via Prime Therapeutics PBM
- Out-of-network reductions citing UCR
- Specialty drug prior auth
SECUKINUMAB (Cosentyx)-specific denial patterns and context
Across payers (not just Florida Blue), SECUKINUMAB (Cosentyx)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring TNF-inhibitor before IL-17
- PASI score threshold not documented
- Indication-specific PA (PsA vs ankylosing spondylitis vs HS)
- Non-formulary in favor of IL-23 class
Brand: Cosentyx. IL-17A inhibitor. Expanded indications now include moderate-to-severe hidradenitis suppurativa (FDA approval October 2023). Self-administered subQ; loading then monthly maintenance.
Manufacturer patient-assistance program: Cosentyx Connect — relevant when a Florida Blue denial sticks and the patient needs bridge access while appealing.
How Florida Blue approaches Biologic drugs (mAbs and biosimilars) PAs
Florida Blue's Biologic drugs (mAbs and biosimilars) reviewer typically anchors SECUKINUMAB (COSENTYX) prior-auth decisions on step therapy via prime therapeutics pbm and specialty drug prior auth. Pharmacy-benefit review for SECUKINUMAB (COSENTYX) at Florida Blue is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Florida Blue's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Florida Blue is domiciled in FL, so unresolved appeals escalate to the FL insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for Florida (~5M members).
If the PA is denied
Florida Blue gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.floridablue.com) with the same packet plus a peer-reviewed citation supporting SECUKINUMAB (Cosentyx)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Florida Blue denial on DenialHelp.
Contact Florida Blue
- Provider portal: https://providers.floridablue.com
Frequently asked questions
What documentation does Florida Blue need for SECUKINUMAB (Cosentyx) prior auth?
Florida Blue's typical PA packet for SECUKINUMAB (Cosentyx): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-17A Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Florida Blue?
Standard SECUKINUMAB (Cosentyx) PA decisions at Florida Blue: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Florida Blue most often reject SECUKINUMAB (Cosentyx) for?
Across Florida Blue's book the common rejection patterns include: Marketplace narrow-network denials (BlueCare, myBlue); Step therapy via Prime Therapeutics PBM; Out-of-network reductions citing UCR. For SECUKINUMAB (Cosentyx) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Florida Blue typically require before approving SECUKINUMAB (COSENTYX)?
Florida Blue's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For SECUKINUMAB (COSENTYX), attach the specific disease-activity instrument Florida Blue accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Florida Blue fully-insured policies sits with the FL insurance department.
How do I prep for a peer-to-peer with Florida Blue on SECUKINUMAB (Cosentyx)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the SECUKINUMAB (Cosentyx) PA packet
Open ApprovalHelp — generate a SECUKINUMAB (Cosentyx) prior-auth packet tailored to Florida Blue's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com